Table 1 Baseline patient characteristics are shown
Mild/moderate | Severe | p value | |
|---|---|---|---|
Number of patients(n) (mild/moderate) | 50 (21/29) | 12 | |
Observation period(n), 3 month/1 year | 50/23 | 12/0 | |
Age(y), (sd) | 47.1 (9.6) | 47.9 (10.6) | 0.8225 |
Female(n),/Male(n) | 26/24 | 6/6 | 0.9009 |
Diagnostic history of asthma,n(%) | 50 (100) | 12 (100) | < 0.0001 |
Undergoing asthma treatment,n (yes/no) | 34/16 | 12/0 (100) | 0.0229 |
Treatment step (GINA) 1–5,n | 2.5 | 5 | < 0.0001 |
Previous antibody therapy,n(%) | 1 (2) | 3 (25) | 0.0036 |
Undergoing OCS,n(%) | 49 (98) | 12 (92) | 0.0229 |
OCSdose(mg), (sd) | 4.7 (0.9) | 3.8 (2.0) | 0.0225 |
Aspirin intolerance,n(%) | 20 (40) | 2 (15.3) | 0.0972 |
Asthma control test, (sd) | 23.2 (3.0) | 22.0 (3.9) | 0.2571 |
IgE, IU/mL (sd) | 385 (522) | 326 (207) | 0.7165 |
Blood eosinophil count, cells/uL, (sd) | 438 (459) | 298 (174) | 0.3064 |
FeNO (ppb),(sd) | 57.7 (46.6) | 75.3 (72.7) | 0.302 |
Spirometry (pre treatment) | |||
FEV1 (L), (sd) | 2.9 (0.8) | 2.9 (0.8) | 0.9074 |
%FEV1 (%), (sd) | 98.5 (16.4) | 94.8 (21.1) | 0.5192 |
FEV1%(G) (%), (sd) | 81.6 (5.9) | 77.8 (8.3) | 0.071 |
%FVC (%), (sd) | 106 (18.5) | 108 (21.1) | 0.9197 |
Respiratory impedance (pre treatment) | |||
R5 (kPa/(L/s)), (sd) | 3.4 (1.0) | 3.1 (1.3) | 0.4848 |
R20 (kPa/(L/s)), (sd) | 2.9 (1.0) | 2.6 (1.1) | 0.3052 |
X5 (kPa/(L/s)), (sd) | -0.4 (0.8) | -0.4 (0.5) | 0.9372 |
Fres (1/s), (sd) | 7.8 (3.1) | 8.0 (3.2) | 0.4194 |